Leaders | Poor prescription

America’s moves against Chinese biotech will hurt patients at home

The motives behind the BIOSECURE act are muddy

Judge looking through mallet shaped microscope
Illustration: Travis Constantine

America’s crackdown on Chinese trade is broadening. On the campaign trail on April 17th President Joe Biden proposed tripling tariffs on steel imports, citing China’s unfair trade practices. Having choked off China’s access to advanced semiconductors and moved to ban TikTok, a Chinese-owned social-media app, lawmakers are eyeing a new target: biotechnology. The biosecure act, which has bipartisan support in Congress, proposes to end government contracts for firms that count Chinese biotech companies as clients or suppliers. American officials have previously said they want to guard a “small yard” of sensitive technologies with a “high fence”. This bill illustrates that the yard is getting bigger, with sorry consequences for American consumers.

Explore more

This article appeared in the Leaders section of the print edition under the headline “Poor prescription”

Reasons to be cheerful about Generation Z

From the April 20th 2024 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Leaders

How to respond to the riots on Britain’s streets

The violence demands robust policing, but it also requires cool heads

Is the big state back in Britain?

The risk is not too much interventionism, but too little audacity



Genomic medicines can cost $3m a dose. How to make them affordable

The treatments are marvels of innovation. Their pricing must be inventive, too

Chinese companies are winning the global south

Their expansion abroad holds important lessons for Western incumbents

The Middle East must step back from the brink

That still means starting with a ceasefire in Gaza